Literature DB >> 22527680

Estimation of treatment effects based on possibly misspecified Cox regression.

Satoshi Hattori1, Masayuki Henmi.   

Abstract

In randomized clinical trials, a treatment effect on a time-to-event endpoint is often estimated by the Cox proportional hazards model. The maximum partial likelihood estimator does not make sense if the proportional hazard assumption is violated. Xu and O'Quigley (Biostatistics 1:423-439, 2000) proposed an estimating equation, which provides an interpretable estimator for the treatment effect under model misspecification. Namely it provides a consistent estimator for the log-hazard ratio among the treatment groups if the model is correctly specified, and it is interpreted as an average log-hazard ratio over time even if misspecified. However, the method requires the assumption that censoring is independent of treatment group, which is more restricted than that for the maximum partial likelihood estimator and is often violated in practice. In this paper, we propose an alternative estimating equation. Our method provides an estimator of the same property as that of Xu and O'Quigley under the usual assumption for the maximum partial likelihood estimation. We show that our estimator is consistent and asymptotically normal, and derive a consistent estimator of the asymptotic variance. If the proportional hazards assumption holds, the efficiency of the estimator can be improved by applying the covariate adjustment method based on the semiparametric theory proposed by Lu and Tsiatis (Biometrika 95:679-694, 2008).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527680     DOI: 10.1007/s10985-012-9222-8

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  4 in total

1.  A semiparametric estimate of treatment effects with censored data.

Authors:  R Xu; D P Harrington
Journal:  Biometrics       Date:  2001-09       Impact factor: 2.571

2.  Estimating average regression effect under non-proportional hazards.

Authors:  R Xu; J O'Quigley
Journal:  Biostatistics       Date:  2000-12       Impact factor: 5.899

3.  Committee for Proprietary Medicinal Products (CPMP): points to consider on adjustment for baseline covariates.

Authors: 
Journal:  Stat Med       Date:  2004-03-15       Impact factor: 2.373

4.  Analysis of survival data by the proportional odds model.

Authors:  S Bennett
Journal:  Stat Med       Date:  1983 Apr-Jun       Impact factor: 2.373

  4 in total
  2 in total

1.  Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit.

Authors:  Julien Péron; Alexandre Lambert; Stephane Munier; Brice Ozenne; Joris Giai; Pascal Roy; Stéphane Dalle; Abigirl Machingura; Delphine Maucort-Boulch; Marc Buyse
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

2.  Quantifying treatment effects using the personalized chance of longer survival.

Authors:  Ying-Qi Zhao; Mary W Redman; Michael L LeBlanc
Journal:  Stat Med       Date:  2019-09-09       Impact factor: 2.373

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.